
Explore the infographic to discover key insights from the upcoming 4Q PitchBook-NVCA Venture Monitor. For a complete analysis of VC activity, sign up to receive the full report—we’ll send it to you as soon as it publishes on Jan. 17.

Explore the infographic to discover key insights from the upcoming 4Q PitchBook-NVCA Venture Monitor. For a complete analysis of VC activity, sign up to receive the full report—we’ll send it to you as soon as it publishes on Jan. 17.

Grants up to $1 million are available from the US-Israel Bi-national R&D (BIRD) Foundation to support new product development R&D, conducted as a joint project between American and Israeli companies. The grants are only to be repaid if the resulting technology successfully achieves sales in the market. BIRD’s wide-ranging scope extends to Agriculture, Communications, Life Sciences, Electronics, Software, Homeland Security, Renewable and Alternative Energy and more. The Maryland/Israel Development Center (MIDC) coordinates the BIRD program for our state.

TAI Diagnostics, a developer of diagnostic tests for monitoring the health of transplanted organs, said on Monday that it has closed a $10 million Series A preferred equity financing.

Greater Washington had its second-biggest venture funding year in at least a decade in 2017, with startups across the metro area raking in more than $1.55 billion.

The pharma and biotech industry will send billions of dollars back to the United States as a result of President Donald Trump’s tax overhaul, Alexandria Real Estate (ARE) Chairman Joel Marcus said on Monday.

Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced the formal launch of the Alexandria Seed Capital Platform, an innovative funding model that brings together leaders from across the life science community to catalyze seed-stage investment in the most promising life science startups.

Roche Holding AG (ROG.EB) said Monday that it has entered into a strategic partnership with GE Healthcare to jointly develop and market a digital clinical-decision support platform.

RightEye LLC, an award-winning technology innovator using eye tracking to revolutionize patient care and vision performance, announced today it will be debuting its new RightEye EyeQ system tonight at CES Unveiled Las Vegas at 5:00 p.m. at the Mandalay Bay Shorelines Exhibit Hall in Las Vegas, Nevada. EyeQ gives people a closer look at their health using quick, computer game-style vision tests on an eye-tracking computer. The tests, which only take a few minutes, generate an instant EyeQ Report that provides results in an easy-to-understand format to support discussion with doctors on diagnosis and recommended therapies.

The use of biomaterials, such as microneedles and nanoparticles, in immunotherapy and vaccine research is a hot topic in bioengineering. But to get the maximum return on investment in these ideas, they need to be seeded among clinicians, according to Christopher Jewell, Ph.D., associate professor in the Fischell Department of Bioengineering at the University of Maryland. Jewell is the principal author on a new paper in Trends in Immunology that reviews the current state of biomaterials research with an eye toward inspiring multidisciplinary teams of engineers and clinicians to solve some of the complex problems in immunology today.

A drug development company has raised $76 million from investors in China, the United States, and Korea to move its headquarters to the Philadelphia area from Jinan, China, and bring treatments developed by China-based scientists through U.S. clinical testing to patients here.